Among these, T-DXd has shown broad antitumor activity due to its high drug-to-antibody ratio (8:1) and bystander effect, earning FDA approval for HER2-positive and HER2-low breast cancer, ERBB2-mutant NSCLC, and HER2-positive gastric cancers.16 Here, ERBB2 is linked to breast carcinoma.